This small cap pharma company received GMP certification from ANVISA Brazil; Check if you hold it!

This financial success paves the way for the swift registration of the company's remaining APIs.

Supriya Lifescience Ltd (SLL) has reached a significant financial milestone, securing the coveted Good Manufacturing Practice (GMP) certification from Brazil's Regulatory Authority, ANVISA, for its manufacturing facility in Lote Parshuram. The Chairman and Managing Director proudly declared the successful clearance of the rigorous GMP inspection at the Lote Factory, attaining a flawless "Zero" Observation for Compliance. This achievement not only underscores Supriya's financial dedication to the highest quality standards but also highlights the financial excellence of its smart manufacturing practices.

The positive financial outcomes of this audit extend further, marking the registration of 8 Active Pharmaceutical Ingredients (APIs) with CADIFA. This financial success paves the way for the swift registration of the company's remaining APIs. The financial significance of this accomplishment positions Supriya Lifescience Ltd. for enhanced market presence in the lucrative Brazilian Pharmaceutical market. The financial community recognizes ANVISA's certification for its stringent financial requirements, adding substantial financial value to Supriya's profile.

Company Overview:

SLL, established in 1987, boasts a state-of-the-art facility certified by USFDA, EDQM, EUGMP, NMPA, and Health Canada. With a strong R&D foundation, 14 active USDMFs, 8 active CEPs, and geographically diversified sales across 86 countries, SLL has established itself as a reliable player in the global API market. Ethical values, EHS compliance, and a focus on both innovator and generic APIs & Intermediates, along with CDMO partnerships, underpin the company's core business.

Future Outlook: Charting a Course for Growth

R&D Expansion:

• The operational 800 Sqm Lote Parshuram R&D lab will focus on lifecycle management, backward integration, new product development, and CMO/CDMO opportunities.
• The upcoming Ambernath R&D lab, to be operational by Q3FY24, will fuel the next phase of expansion.
• These centers will aid in developing APIs to complement the existing product portfolio.

Market Reach:

• Expanding the controlled drugs portfolio with identified APIs in the development pipeline.
• Evaluating product portfolio expansion in anti-diabetic and CNS segments.
• Strengthening presence in existing markets through a dedicated sales team and regulatory team registrations.
• Actively pursuing business expansion in North America, Japan, Australia, and New Zealand.

CMO/CDMO Focus:

• Leveraging its expertise in large-scale special chemical manufacturing and complex process chemistry, SLL is actively pursuing CMO/CDMO partnerships.
• A recently announced 10-year CMO contract with a leading European company is expected to generate peak revenue of INR 40 crores/year starting from FY27.
• SLL has identified similar opportunities in the API and advanced intermediate space, along with exploring additional potential partnerships.

Capacity Enhancement:

• The upcoming 340 KL capacity E block at Lote Parshuram, to be operational by Q3FY24.
• A new 70 KL manufacturing block and R&D facility with a pilot plant at Ambernath.
• These projects will increase the total capacity from 597 KL to 900 KL by Q3 FY24.
   

Supriya Lifesciences' Brazil GMP certification and its strategic future plans position the company for continued growth and success in the global API market. With a focus on R&D expansion, market reach, and strategic partnerships, SLL is well poised to capitalize on emerging opportunities and deliver value to its stakeholders.

The company has delivered around 95.5 per cent returns from 52 week lows. Investors should keep an eye on this Small-Cap pharma stock.

Disclaimer: The article is for informational purposes only and not investment advice.